BioMarin Acquires Inozyme to Bolster Late-Stage ERT BMN 401

BioMarin Pharmaceutical has acquired Inozyme Pharma, adding late-stage enzyme replacement therapy BMN 401 to its portfolio. BMN 401 is being developed for the treatment of mucopolysaccharidosis VI (MPS VI), a rare genetic disorder. The acquisition expands BioMarin's enzyme replacement therapy offerings and reinforces its position as a leader in rare disease treatment.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has recently acquired Inozyme Pharma, Inc. (Inozyme), adding late-stage enzyme replacement therapy BMN 401 to its portfolio. The acquisition, completed on July 1, 2025, aims to expand BioMarin's enzyme replacement therapy offerings and reinforce its position as a leader in rare disease treatment [1].

BMN 401, formerly known as INZ-701, is being developed for the treatment of mucopolysaccharidosis VI (MPS VI), a rare genetic disorder. The acquisition of Inozyme is part of BioMarin's broader strategy to strengthen its pipeline and enhance its market position in the rare disease sector [1].

The second quarter of 2025 saw strong financial performance for BioMarin, with total revenues of $825 million, representing a 16% year-over-year increase. The company's GAAP Diluted Earnings Per Share (EPS) reached $1.23, a 124% year-over-year increase, while Non-GAAP Diluted EPS reached $1.44, a 50% year-over-year increase [1].

BioMarin's acquisition of Inozyme is expected to bring additional value to the company's portfolio. The company is committed to advancing BMN 401 for the treatment of MPS VI, with initial pivotal data readout for the ENERGY 3 study anticipated in the first half of 2026. The potential launch of BMN 401 is expected in 2027, further bolstering BioMarin's rare disease treatment offerings [1].

The acquisition of Inozyme is a significant move for BioMarin, expanding its capabilities in the rare disease space and positioning it as a leader in the development of innovative therapies for rare genetic disorders.

References:
[1] https://www.biospace.com/press-releases/biomarin-reports-strong-second-quarter-2025-results-and-raises-full-year-guidance%C2%B9-for-total-revenues-non-gaap-operating-margin-and-non-gaap-diluted-eps